ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1580

Whole Blood Gene Expression and eQTL Analysis Implicate GGT7 and FADS2 in Gout Pathogenesis
Abstract Number: 1743

Whole Blood Hydroxychloroquine Levels Do Not Correlate with QTc Intervals in a Cohort of 84 SLE Patients: Evidence That Antimalarials Are Not Associated with Cardiac Conduction System Toxicity
Abstract Number: 0927

Whole Blood Transcriptional Changes Following Treatment with Filgotinib in Patients with Ankylosing Spondylitis
Abstract Number: 1353

Whole Blood Transcriptional Changes Following Treatment with Filgotinib in Patients with Psoriatic Arthritis
Abstract Number: 0366

Why Is It so Difficult for AxSpA Patients to Find a Job? Results from the European Map of Axial Spondyloarthritis (EMAS)
Abstract Number: 1202

Widespread but Not Regional Non-articular Pain Influences Patient and Rheumatologist Reported Change in Clinical Disease Activity Index Scores over Time – Implications for Using Patient Ratings in Telehealth – a Study from the Canadian Early Arthritis Cohort
Abstract Number: 1758

WITHDRAWN
Abstract Number: 1656

Women with Rheumatoid Arthritis Have More Multimorbidity Than Men in a Large Nationwide US Study
Abstract Number: 0239

Work Disability Associated with Fatigue in Patients with Psoriatic Arthritis – a Retrospective Study Using Claims Data, 2009-2019
Abstract Number: 0358

Work Participation in Patients with Axial Spondyloarthritis in Germany: Results from a Multicenter, Observational Survey
Abstract Number: 0227

Work Participation Is Impaired Months Before Clinical Arthritis Is Apparent
Abstract Number: 0575

World Mortality of Spondyloarthritis and Inflammatory Bowel Diseases in 2015 and Its Evolution Between 2001 and 2015
Abstract Number: 0119

Worsened Depression but Improved Fatigue Were the Main Impacts of Severe Lockdown in Non- COVID Infected Australian Fibromyalgia Patients
Abstract Number: 1302

Year-3 Observational Follow-up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE Who Completed a Phase 4, 52-Week, Randomized, Double-Blind Placebo-Controlled Safety Study
Abstract Number: 1201

Younger Age and Smoking Status Are Associated with Delayed Diagnosis of Rheumatoid Arthritis in a U.S. Veteran Population

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].